Previous 10 | Next 10 |
PETACH TIKVA, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the JMP Securities 2022 Life S...
Locally Administered Docetaxel Through Extended-Release Delivery via the Company’s PLEX Technology Offers Potentially Enhanced Adjuvant Chemotherapy Option PETACH TIKVA, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPi...
Following Unblinded Interim Efficacy Analysis, Data Safety Monitoring Board Recently Recommended Concluding Study at 950 Patients, the Minimum Number of Patients Targeted Top-line Results Expected by End of Q3 2022; Potential NDA and MAA Submissions Targeted for H1 2023 ...
• Enrollment of 950 Patients, the Minimum Number of Patients Targeted for the SHIELD I Study, Expected Within Days • Top-line Results Expected by End of Q3 2022; Potential NDA and MAA Submissions Targeted for H1 2023 • Conference Call...
PolyPid (NASDAQ: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, e...
PolyPid Ltd. (PYPD) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Bob Yedid - Investor Relations, LifeSci Advisors Amir Weisberg - Chief Executive Officer Dikla Czaczkes Akselbrad - Executive Vice President and Chief Financial Officer Ori Warshavsky - Chief Ope...
PolyPid press release (NASDAQ:PYPD): Q1 GAAP EPS of $0.63 beats by $1.29. Cash and cash equivalents of $11.44M For further details see: PolyPid GAAP EPS of $0.63 beats by $1.29
• Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Soft Tissue Surgery Expected to Occur Imminently • Recruitment Progressing as Planned with A pproximately 900 Patien...
PETACH TIKVA, Israel, April 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2022 financial r...
Presentation evaluates the effect of D-PLEX 100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients PETACH TIKVA, Israel, April 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “...
News, Short Squeeze, Breakout and More Instantly...
After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID Levels Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Impact Payer Costs Approximately 250 Patients of a Planned...
Submitted Revised Protocol for SHIELD II Phase 3 Trial to FDA to Evaluate D-PLEX 100 for Prevention of Abdominal Colorectal Surgical Site Infections ; Recruitment Expected to Re sume Imminently Received Advice from the Swedish Medical Prod...
PETACH TIKVA, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2023 financial results...